Enlivex Therapeutics Ltd. Annual Net Income (Loss) Attributable to Parent in USD from 2012 to 2023

Taxonomy & unit: us-gaap: USD
Description: The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary: Enlivex Therapeutics Ltd. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2012 to 2023.
Enlivex Therapeutics Ltd. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$3.1M, a 54.4% increase year-over-year.
Enlivex Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.1M, a 6.41% increase from 2022.
Enlivex Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2022 was -$31.1M, a 115% decline from 2021.
Enlivex Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2021 was -$14.5M, a 22.4% decline from 2020.

Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)

Net Income (Loss) Attributable to Parent, Annual (USD)

Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
2023	-$29.1M	+$1.99M	+6.41%	Jan 1, 2023	Dec 31, 2023	20-F	2024-04-30
2022	-$31.1M	-$16.6M	-115%	Jan 1, 2022	Dec 31, 2022	20-F	2024-04-30
2021	-$14.5M	-$2.64M	-22.4%	Jan 1, 2021	Dec 31, 2021	20-F	2024-04-30
2020	-$11.8M	-$2.44M	-26%	Jan 1, 2020	Dec 31, 2020	20-F	2023-04-10
2019	-$9.38M	-$5.14M	-121%	Jan 1, 2019	Dec 31, 2019	20-F	2022-04-29
2018	-$4.24M	-$1.74M	-69.4%	Jan 1, 2018	Dec 31, 2018	20-F	2021-04-30
2017	-$2.5M	+$13.5M	+84.4%	Jan 1, 2017	Dec 31, 2017	20-F	2020-04-30
2016	-$16M	-$657K	-4.28%	Jan 1, 2016	Dec 31, 2016	20-F/A	2020-01-23
2015	-$15.4M	-$8.34M	-119%	Jan 1, 2015	Dec 31, 2015	20-F	2018-04-23
2014	-$7.02M	-$5.88M	-513%	Jan 1, 2014	Dec 31, 2014	20-F	2017-02-24
2013	-$1.15M	-$916K	-400%	Jan 1, 2013	Dec 31, 2013	20-F	2016-03-29
2012	-$229K			Jan 1, 2012	Dec 31, 2012	20-F	2015-03-31

* An asterisk sign (*) next to the value indicates that the value is likely invalid.